Xspray Pharma Q1 2024: Reveal of XS025 and PDUFA is nearing
Research Update
2024-05-13
08:10
Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report. The company has recently raised SEK100m through TO6, unveiled XS025 targeting cabozantinib, and the Dasynoc PDUFA date is less than three months away. We raise our base case.
FE
Filip Einarsson
Disclosures and disclaimers